What is the catalog number for Pexidartinib?

The catalog number for Pexidartinib is HY-16749.

What sizes are available for Pexidartinib?

Pexidartinib is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g, 10 g, 20 g.

How many pack sizes does Pexidartinib come in?

Pexidartinib is available in 12 different pack sizes.

Is Pexidartinib in stock?

Pexidartinib is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Pexidartinib?

Pexidartinib is manufactured by QuantiMol.

What is the estimated delivery time for Pexidartinib?

Estimated delivery time for Pexidartinib is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Pexidartinib?

The safety data sheet for Pexidartinib is available here: http://file.medchemexpress.com/batch_PDF/HY-16749/Pexidartinib-SDS-MedChemExpress.pdf.

What do I do if this product arrives with reduced ice or a damaged cold-chain package?

Report this to us immediately with photos and your order reference. Our specialists will assess whether the product is still usable given the cold-chain interruption, and will arrange a replacement or credit if it isn’t.

What host species was used to raise this antibody?

The host species used in production is listed under product specifications on the datasheet, and is relevant when selecting a compatible secondary antibody for your assay.

What is the difference between this product and a similar catalogue number?

Differences typically involve clone, conjugate, host species, or validated applications. Compare the respective datasheets, or contact us with both catalogue numbers for a direct comparison.

Pexidartinib

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity[1].

Product Specifications

CAS Number

1029044-16-3

Product Name Alternative

PLX-3397

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; c-Fms; c-Kit

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Pexidartinib.html

Purity

99.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F

Molecular Formula

C20H15ClF3N5

Molecular Weight

417.81

Precautions

H302, H315, H319, H335

References & Citations

[1]DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1 (1) :54-67.|[2]Kuse Y, et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018.|[3]Lee JH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019 Mar 2.|[4]Merry TL, et al. The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. Int J Obes (Lond) . 2020;44 (1) :245-253.|[5]Luo L, et al. Intermittent theta-burst stimulation improves motor function by inhibiting neuronal pyroptosis and regulating microglial polarization via TLR4/NFκB/NLRP3 signaling pathway in cerebral ischemic mice. J Neuroinflammation. 2022 Jun 11;19 (1) :141.|[6]Chadarevian JP, et al. Engineering an inhibitor-resistant human CSF1R variant for microglia replacement. J Exp Med. 2023 Mar 6;220 (3) :e20220857.